Compare Ascendis Pharma A/S (ASND) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Oatly Group AB - ADR — how do they compare? Ascendis Pharma A/S trades at $256.72 (market cap $16.67B), while Oatly Group AB - ADR trades at $13.11 (market cap $415.98M). The key difference: Ascendis Pharma A/S is far larger — about 40.1× Oatly Group AB - ADR's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| ASND | OTLY | |
|---|---|---|
Market Cap | $16.67B | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $18.54 |
52-Week Low | $189.74 | $8.03 |
Enterprise Value | $17.04B | $920.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
OTLY trades at $13.12, down 4.37% today, but maintains a bullish technical outlook with strong moving average and oscillator signals. The company reported Q2 2026 revenue growth and raised full-year guidance, showing progress toward profitability with improving gross margins. However, negative net income and cash flow challenges persist, with the stock trading at a low P/S ratio of 0.44 but elevated P/B of 79.9.
The investment case hinges on OTLY's operational turnaround and revenue acceleration, but significant risks remain from cash burn and high debt levels. Analyst sentiment is mixed with 44% buy ratings, while technical indicators suggest near-term support at $13. The path to sustainable profitability remains the key catalyst for stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
